Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10743MR)

This product GTTS-WQ10743MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10743MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14394MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ13304MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ1785MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ10789MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ3904MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ9868MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ7084MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ15784MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW